Our first stop on June 11th was at Pluristem, a biotech company in Haifa that manufactures its own brand of modified placental cells for use in a wide variety of therapies. Pluristems's patented PLX cells are currently in different stages of clinical trials for indications ranging from myocardial infarctions to preeclampsia to Buerger's disease, an FDA designated orphan illness. Ohad Karnieli, Pluristem's Vice President of Technology, gave us a thorough explanation of his company's goals, process, and business model and easily fielded our many questions, both technical and otherwise.